Ph.D., CEO/Co-founder, ImpriMed
Biography
Sungwon Lim is a bioengineer/entrepreneur with 20 years of collective experiences in academia, pharmaceutical companies, and biotech industries. He co-founded ImpriMed, Inc. with a strong motivation to innovate a way to help cancer patients who need an effective treatment ‘today', by optimizing and personalizing drug treatment options that are currently available in our medical cabinet. His team is building a comparative oncology platform to develop and prove new cell-based, functional precision medicine technologies in the veterinary oncology space first, at a significantly higher speed with by far more comprehensive data compared to the human oncology space, and then translate the collected database into human cancer care. Sungwon graduated Stanford University with Ph.D. degree in Bioengineering, and has M.S. in Translational Medicine at U.C. Berkeley and U.C. San Francisco, and B.S. in Chemical Engineering at Korea Advanced Institute of Science and Technology.
Clinical Dx Showcase:
ImpriMed
ImpriMed provides a personalized drug testing service designed for pets with cancer.
From Dog To Human: Precision Medicine For Comparative Oncology
ImpriMed develops functional precision medicine technologies to help veterinary oncologists find out the most effective treatment options for individual cancer patients by building up a patient-derived database for pet cancer treatment, which can be eventually translated into human cancer care.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 22 2.30 P.M.-3.45 P.M.,Track 7 - January 23 1.15 P.M.-1.30 P.M.,Track 6 - January 24 9.00 A.M.-1.15 P.M.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
